Gils A, Declerck P J
Laboratory for Pharmaceutical Biology and Phytopharmacology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.
J Biol Chem. 1997 May 9;272(19):12662-6. doi: 10.1074/jbc.272.19.12662.
Plasminogen activator inhibitor-1 (PAI-1) is a unique member of the serpin superfamily. The alternative behavior of PAI-1 as an inhibitor, a non-inhibitory substrate, or a non-reactive latent form has been shown to be dependent on the initial conformation. In this study, we have evaluated the effect of a substitution outside the reactive site loop (P18) or in the reactive site loop (P6 and P10) on proteinase specificity and conformational transitions in PAI-1. Wild-type PAI-1 (wtPAI-1) revealed the same conformational distribution pattern toward tissue-type plasminogen activator (t-PA) as toward urokinase-type plasminogen activator (u-PA) (i.e. 53 +/- 6. 9% active, 36 +/- 6.8% latent, and 12 +/- 1.9% substrate). Inactivation of wtPAI-1 resulted in the conversion of the labile active form into the latent form while the stable substrate form remained unchanged. PAI-1-P6 (Val --> Pro at P6) revealed a target specificity for t-PA (39 +/- 7% versus 3 +/- 2% of the theoretical maximal value toward t-PA and u-PA, respectively), PAI-1-P10 (Ser --> Pro at P10) was 4-fold more active toward u-PA than toward t-PA, and PAI-1-P18 (Asn --> Pro at P18) exhibited inhibitory properties exclusively toward u-PA (41 +/- 10%). Surprisingly, inactivation of these mutants revealed functional and conformational transitions distinct from those observed for wtPAI-1. Inactivation of PAI-1-P6(Val --> Pro) resulted in a total conversion of the active form into the latent form and in a partial conversion of the substrate form into the latent form. The active forms of both PAI-1-P10(Ser --> Pro) and PAI-1-P18(Asn --> Pro) are also labile but, in contrast to the active form of wtPAI-1, convert into substrate forms. Based on the existence of various conformations of PAI-1, we propose an alternative reaction scheme describing the putative interactions between serpins and their target proteinases. The unusual conformational and functional flexibility of PAI-1 that, according to the current study, appears not to be restricted to the reactive site loop further underlines the importance of potential structural rearrangements (e.g. upon binding to cofactors) in PAI-1 (or serpins in general) for its functional behavior at particular biological sites.
纤溶酶原激活物抑制剂-1(PAI-1)是丝氨酸蛋白酶抑制剂超家族中的独特成员。PAI-1作为抑制剂、非抑制性底物或无反应性潜在形式的不同行为已被证明取决于其初始构象。在本研究中,我们评估了反应位点环外(P18)或反应位点环内(P6和P10)的取代对PAI-1中蛋白酶特异性和构象转变的影响。野生型PAI-1(wtPAI-1)对组织型纤溶酶原激活物(t-PA)和尿激酶型纤溶酶原激活物(u-PA)显示出相同的构象分布模式(即53±6.9%为活性形式,36±6.8%为潜在形式,12±1.9%为底物形式)。wtPAI-1的失活导致不稳定的活性形式转变为潜在形式,而稳定的底物形式保持不变。PAI-1-P6(P6处的Val→Pro)对t-PA显示出靶标特异性(分别为理论最大值的39±7%和3±2%,对应于t-PA和u-PA),PAI-1-P10(P10处的Ser→Pro)对u-PA的活性比对t-PA高4倍,并且PAI-1-P18(P18处的Asn→Pro)仅对u-PA表现出抑制特性(41±10%)。令人惊讶的是,这些突变体的失活显示出与wtPAI-1不同的功能和构象转变。PAI-1-P6(Val→Pro)的失活导致活性形式完全转变为潜在形式,底物形式部分转变为潜在形式。PAI-1-P10(Ser→Pro)和PAI-1-P18(Asn→Pro)的活性形式也不稳定,但与wtPAI-1的活性形式不同,它们转变为底物形式。基于PAI-1存在多种构象,我们提出了一种替代反应方案,描述丝氨酸蛋白酶抑制剂与其靶标蛋白酶之间的假定相互作用。根据当前研究,PAI-1异常的构象和功能灵活性似乎不限于反应位点环,这进一步强调了PAI-1(或一般丝氨酸蛋白酶抑制剂)中潜在的结构重排(例如与辅因子结合时)对其在特定生物位点的功能行为的重要性。